Evidence map›Paper›PMID 32764708›Full record

ArticleScientific reports2020

Pharmacological activation of the circadian component REV-ERB inhibits HIV-1 replication.

Helene Borrmann, Rhianna Davies, Matthew Dickinson, Isabela Pedroza-Pacheco, Mirjam Schilling, Alun Vaughan-Jackson, Andrea Magri, William James, Peter Balfe, Persephone Borrow and 2 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
3.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 43 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. The role of latency reversal in HIV cure strategies.Journal of medical primatology · 2022
    Review
  13. Review
  14. Hepatitis B and circadian rhythm of the liver.World journal of gastroenterology · 2022
    Review
  15. Circadian rhythms in infectious diseases and symbiosis.Seminars in cell & developmental biology · 2022
    Review
  16. Review
  17. Review
  18. Observational
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Helene Borrmann *Nuffield Department of Clinical Medicine, University of Oxford, Oxford, OX3 7FZ, UK.
Rhianna Davies *Institute of Immunity and Immunotherapy, University of Birmingham, Birmingham, B15 2TT, UK.
Matthew DickinsonNuffield Department of Clinical Medicine, University of Oxford, Oxford, OX3 7FZ, UK.
Isabela Pedroza-PachecoNuffield Department of Clinical Medicine, University of Oxford, Oxford, OX3 7FZ, UK.
Mirjam SchillingNuffield Department of Clinical Medicine, University of Oxford, Oxford, OX3 7FZ, UK.
Alun Vaughan-JacksonSir William Dunn School of Pathology, University of Oxford, Oxford, OX1 3RE, UK.
Andrea MagriNuffield Department of Clinical Medicine, University of Oxford, Oxford, OX3 7FZ, UK.
William JamesSir William Dunn School of Pathology, University of Oxford, Oxford, OX1 3RE, UK.
Peter BalfeNuffield Department of Clinical Medicine, University of Oxford, Oxford, OX3 7FZ, UK.
Persephone BorrowNuffield Department of Clinical Medicine, University of Oxford, Oxford, OX3 7FZ, UK.
Jane A McKeatingNuffield Department of Clinical Medicine, University of Oxford, Oxford, OX3 7FZ, UK.
Xiaodong ZhuangNuffield Department of Clinical Medicine, University of Oxford, Oxford, OX3 7FZ, UK. xiaodong.zhuang@ndm.ox.ac.uk.
University of Oxford · GBUniversity of Birmingham · GB

Funding

Collaboratory of AIDS Researchers for Eradication (CARE)UM1AI126619 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI MARGOLIS, DAVID M. · 2016 to 2020
$23.2M
Restriction of HIV-1 transmission by type 1 interferonsR01AI114266 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI HAHN, BEATRICE H · 2014 to 2018
$3.2M
Medical Research Council G0400802Medical Research Council G0801976Medical Research Council MR/R022011/1NIAID NIH HHS R01 AI114266NIAID NIH HHS UM1 AI126619Wellcome TrustWellcome Trust IA 200838/Z/16/Z
6 · The paper itself

Abstract

Human immunodeficiency virus 1 (HIV-1) is a life-threatening pathogen that still lacks a curative therapy or vaccine. Despite the reduction in AIDS-related deaths achieved by current antiretroviral therapies, drawbacks including drug resistance and the failure to eradicate infection highlight the need to identify new pathways to target the infection. Circadian rhythms are endogenous 24-h oscillations which regulate physiological processes including immune responses to infection, and there is an emerging role for the circadian components in regulating viral replication. The molecular clock consists of transcriptional/translational feedback loops that generate rhythms. In mammals, BMAL1 and CLOCK activate rhythmic transcription of genes including the nuclear receptor REV-ERBα, which represses BMAL1 and plays an essential role in sustaining a functional clock. We investigated whether REV-ERB activity regulates HIV-1 replication and found REV-ERB agonists inhibited HIV-1 promoter activity in cell lines, primary human CD4 T cells and macrophages, whilst antagonism or genetic disruption of REV-ERB increased promoter activity. The REV-ERB agonist SR9009 inhibited promoter activity of diverse HIV-subtypes and HIV-1 replication in primary T cells. This study shows a role for REV-ERB synthetic agonists to inhibit HIV-1 LTR promoter activity and viral replication, supporting a role for circadian clock components in regulating HIV-1 replication.

Indexed as

Antiviral AgentsCD4-Positive T-LymphocytesCell LineCircadian ClocksHIV-1HIV Long Terminal RepeatHumansJurkat CellsMacrophagesPromoter Regions, GeneticPyrrolidinesReceptors, Thyroid Hormonerev Gene Products, Human Immunodeficiency VirusThiophenesVirus ReplicationAntiviral AgentsPyrrolidinesReceptors, Thyroid Hormonerev Gene Products, Human Immunodeficiency Virusrev protein, Human Immunodeficiency Virus-1SR9009Thiophenes

Identifiers

PMID32764708
PMCPMC7413328
OpenAlexW3047346879

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.